Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2020.00432
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

Liraglutide Improves Non-Alcoholic Fatty Liver Disease in Diabetic Mice by Modulating Inflammatory Signaling Pathways

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Lactobacillus Rhamnosus GG Protects Against Non-Alcoholic Fatty Liver Disease in Mice

PLoS ONE
Multidisciplinary
2014English

Non-Alcoholic Fatty Liver Disease and Disease Mongering

American Journal of Medicine
Medicine
2019English

Treatment of Non-Alcoholic Fatty Liver Disease

Postgraduate Medical Journal
Medicine
2006English

Pentoxifylline Ameliorates Non-Alcoholic Fatty Liver Disease in Hyperglycaemic and Dyslipidaemic Mice by Upregulating Fatty Acid Β-Oxidation

Scientific Reports
Multidisciplinary
2016English

Randomized Trial Comparing the Effects of Gliclazide, Liraglutide, and Metformin on Diabetes With Non-Alcoholic Fatty Liver Disease

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2017English

Headway and Hurdles in Non-Alcoholic Fatty Liver Disease

Lancet Gastroenterology and Hepatology, The
HepatologyGastroenterology
2020English

Global Perspectives on Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Hepatology
MedicineHepatology
2019English

Resistin Levels in Non-Alcoholic Fatty Liver Disease Pathogenesis

Journal of Translational Internal Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy